oxypurinol
Small moleculeexperimental
Oxipurinol is an inhibitor of xanthine oxidase. It is an active metabolite of allopurinol and it is cleared renally. In cases of renal disease, this metabolite will accumulate to toxic levels. By inhibiting xanthine oxidase, it reduces uric acid production. High serum uric acid levels may result in gout, kidney stones, and other medical conditions. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2003 (NCT00063687)
Timeline
Indications
Mechanism of action
- Xanthine dehydrogenaseINHIBITOR
XDH inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Oc1nc(O)c2cn[nH]c2n1- Mol. weight
- 152.11 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOxipurinol ↗
- ChEMBLCHEMBL859 ↗
Also known as
- 1h-pyrazolo[3,4-d]pyrimidine-4,6(5h,7h)-dione
- 1h-pyrazolo[3,4-d]pyrimidine-4,6(5h,7h)-dione
- 1h-pyrazolo[3,4-d]pyrimidine-4,6-diol
- 1h-pyrazolo[3,4-d]pyrimidine-4,6-diol
- 6-hydroxy allopurinol
- 6-hydroxy allopurinol
- 7,7',8,8'-tetrahydro-beta,beta-carotene-3,3'-diolbeta,beta-carotene-3,3'-diol, 7,7',8,8'-tetradehydro-, (3r,3'r)-
- alloxanthin
- alloxanthin
- alloxanthin
- alloxanthine
- alloxanthine
- beta,beta-carotene-3,3'-diol, 7,7',8,8'-tetradehydro-, (3r,3'r)-
- dhpp
- dhpp
- metabolite of allopurinol
- oxipurinol
- oxipurinol
- oxipurinol
- oxipurinolum
- oxipurinolum
- oxoallopurinol
- oxoallopurinol
- oxyprim
- oxypurinol
- oxypurinol
- oxypurinol
- oxypurinol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00102271 | Phase 1 | Jan 19, 2005 | National Heart, Lung, and Blood Institute (NHLBI) |
| NCT00072826 | Phase 1 | Nov 4, 2003 | National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) |
| NCT00063687 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2003 | Cardiome Pharma, Johns Hopkins University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 2 | 1 | 1 | 2003 |
| Cardiome Pharma | For profit | 1 | 1 | 1 | 2003 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2003 |
| National Institutes of Health (NIH) | Government | 1 | 1 | 1 | 2003 |
4 organizations
Page 1 / 1